FDA approves gene therapy for MPS IIIA
The one-time intravenous treatment uses adeno-associated virus serotype 9 to deliver a functional copy of the SGSH gene.
By
Kathryn Wighton
September 18, 2026
Clinical Scorecard: FDA approves gene therapy for MPS IIIA
At a Glance
Category Detail
Condition Mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A) Key Mechanisms Rebisufligene etisparvovec introduces a functional copy of the SGSH gene using modified adeno-associated virus serotype 9. Target Population Pediatric patients with mucopolysaccharidosis type IIIA. Care Setting Health care setting where infusion reactions can be managed.
Key Highlights
First FDA-approved treatment for MPS IIIA. Single intravenous infusion of rebisufligene etisparvovec. Cognitive function remained stable or improved post-treatment. Adverse reactions include increased liver enzymes, nausea, and thrombotic microangiopathy. Corticosteroids are administered before and after infusion. Guideline-Based Recommendations
Diagnosis
Diagnosis of MPS IIIA should be confirmed through genetic testing. Management
Rebisufligene etisparvovec is indicated for treatment. Monitoring & Follow-up
Monitor cognitive outcomes and adverse reactions post-infusion. Risks
Long-term risk of tumor development due to genomic integration. Patient & Prescribing Data
Pediatric patients diagnosed with MPS IIIA.
Treatment involves a single intravenous infusion with pre- and post-infusion corticosteroids.
Clinical Best Practices
Administer in a setting equipped to manage infusion reactions. Conduct regular monitoring of liver enzymes and cognitive function. Related Resources & Content
